Phio Pharmaceuticals (PHIO) Accumulated Expenses (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Accumulated Expenses came in at $690000.0 in Q1 2026, down 18.15% YoY from $843000.0 in Q1 2025, and down 23.76% on a QoQ basis from $905000.0 in Q4 2025.
Phio Pharmaceuticals (PHIO) Accumulated Expenses (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Accumulated Expenses data on file, last reported at $690000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 18.15% year-over-year to $690000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $690000.0 (down 18.15% YoY) and the FY2025 annual result came in at $905000.0, up 18.77% from the prior year.
- Accumulated Expenses fell to $690000.0 in Q1 2026, from $905000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $2.1 million in Q1 2022 to a low of $690000.0 in Q1 2026.
- A 5-year average of $1.2 million and a median of $1.0 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 79.2% — and 2024, when it plunged 64.71%.
- Tracing PHIO's Accumulated Expenses over 5 years: stood at $1.0 million in 2022, then declined by 8.1% to $942000.0 in 2023, then dropped by 19.11% to $762000.0 in 2024, then grew by 18.77% to $905000.0 in 2025, then slipped by 23.76% to $690000.0 in 2026.
- The last three Accumulated Expenses figures came in at $690000.0 (Q1 2026), $905000.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Phio Pharmaceuticals | 13.77 Mn | 13.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 804,000.00 |
| Mar 31, 2026 | 690,000.00 |
| Dec 31, 2025 | 905,000.00 |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 971,000.00 |
| Mar 31, 2025 | 843,000.00 |
| Dec 31, 2024 | 762,000.00 |
| Sep 30, 2024 | 735,000.00 |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 929,000.00 |
| Dec 31, 2023 | 942,000.00 |
| Sep 30, 2023 | 2.08 Mn |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 1.36 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Jun 30, 2022 | 1.76 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Dec 31, 2021 | 572,000.00 |
| Sep 30, 2021 | 2.06 Mn |